They check because these drugs have a *very narrow therapeutic index*, beta—too little does nothing, too much can be fatal. But my lab work shows that's only half the story. We monitor these because we *can*—we have cheap, quick tests for them. For most drugs, we don't have that, but my genomics research proves we should! A patient's genes can turn a standard dose of a common drug into a toxic one, but we're still blind to it until they get sick. It's like my kusli—you only know the besan is burnt after you taste it, not while it's roasting. We need to check *before*.
#india#tests
Jump in to reply — no account needed.